Inflammation can be described as a complex biochemical response of the body to remove the injurious stimuli and to initiate the healing process. It is known that cardiac surgery and cardiopulmonary bypass (CPB) initiate a systemic inflammatory response syndrome affecting the whole body. This inflammatory reaction may cause postoperative complications, including myocardial dysfunction, lung problems, renal and neurologic dysfunction, bleeding/clotting disorders, liver dysfunction, and multiple organ failure. The magnitude of the inflammatory reaction varies from patient to patient. The inflammatory response is related to the secretion of a large number of mediators and activation of complex body defense systems, including cytokines, vasoactive amines, proteases, reactive oxygen radicals, and the blood cells. Although the inflammatory response itself is a defense mechanism, it is responsible for all cardiovascular and other problems by activating complex body defense systems.
Complement System Sodium Nitroprusside Extracorporeal Circulation Pulmonary Sequestration Extracorporeal Circuit
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Massoudy P, Zahler S, Becker BF, Braun SL, Barankay A, Meisner H. Evidence for inflammatory response of the lungs during coronary artery bypass grafting with cardiopulmonary bypass. Chest. 2001;119:31–6.PubMedCrossRefGoogle Scholar
Cassey WF, Hauser GJ, Hannalah RS, Midgley FM, Khan W. Circulating endotoxin and tumour necrosis factor during paediatric cardiac surgery. Crit Care Med. 1992;20:1090–6.CrossRefGoogle Scholar
Fortenberry JD, Bhardwaj V, Niemer P, et al. Neutrophil and cytokine activation with neonatal extracorporeal membrane oxygenation. J Pediatr. 1996;128:670–8.PubMedCrossRefGoogle Scholar
Gessler P, Pfenninger J, Pfammatter JP, Carrel T, Baenziger O, Dahinden C. Plasma levels of interleukin-8 and expression of interleukin-8 receptors on circulating neutrophils and monocytes after cardiopulmonary bypass in children. J Thorac Cardiovasc Surg. 2003;126:718–25.PubMedCrossRefGoogle Scholar
Jansen NJ, van Oeveren W, van der Brock L, et al. Inhibition by dexamethasone of the reperfusion phenomenon in cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1991;102:515–25.PubMedGoogle Scholar
Sun D, Xu C, Li J, Jiao X, Chen Y. Changes of inflammatory factors in patients with coronary artery disease during perioperation. Zhonghua Wai Ke Za Zhi. 2002;40:571–3.PubMedGoogle Scholar
Khabar KS, elBarbary MA, Khouqeer F, et al. Circulating endotoxins and cytokines after cardiopulmonary bypass: differential correlation with duration of bypass and systemic inflammatory response/multiple organ dysfunction syndromes. Clin Immunol Immunopathol. 1997;85:97–103.PubMedCrossRefGoogle Scholar
Clermont G, Vergely C, de Girard C, Rochette L. Cellular injury associated with extracorporeal circulation. Ann Cardiol Angeiol. 2002;51:38–43.CrossRefGoogle Scholar
Ulus AT, Aksoyek A, Ozkan M, Katircioglu SF, Basu S. Cardiopulmonary bypass as a cause of free radical-induced oxidative stress and enhanced blood-borne isoprostanes in humans. Free Radic Biol Med. 2003;34:911–7.PubMedCrossRefGoogle Scholar
Kirklin JK, Westaby S, Blackstone EH, et al. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1983;86:845–57.PubMedGoogle Scholar
Bronicki RA, Backer CL, Baden HP, Mavroudis C, Crawford SE, Gren TP. Dexamethasone reduces the inflammatory response to cardiopulmonary bypass in children. Ann Thorac Surg. 2000;69:1490–5.PubMedCrossRefGoogle Scholar
Matheve C. Clinical evidence of improved biocompatibility using heparin-coated surfaces. Perfusion. 1996;11:264–9.PubMedCrossRefGoogle Scholar
Moen O, Hogasen K, Fosse E, et al. Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg. 1997;63:105–11.PubMedCrossRefGoogle Scholar
Hamulu A, Discigil B, OZbaran M, et al. Complement consumption during cardiopulmonary bypass: comparison of Duraflo II heparin-coated and uncoated circuits in fully heparinized patients. Perfusion. 1996;11:333–7.PubMedCrossRefGoogle Scholar
Gu YJ, de Vries AJ, Vos P, et al. Leukocyte depletion during cardiac operation. A new approach through the venous bypass circuit. Ann Thorac Surg. 1999;67:604–9.PubMedCrossRefGoogle Scholar
Olivencia-Yurvatti AH, Ferrara CA, Tierney N, Wallace N, MAllet RT. Strategic leukocyte depletion reduces pulmonary microvascular pressure and improves pulmonary status post-cardiopulmonary bypass. Perfusion. 2003;18 suppl 1:23–31.CrossRefGoogle Scholar
Morioka K, Muraoka R, Chiba Y, et al. Leukocyte and platelet depletion with the blood cell separator: effects on lung injury after cardiac surgery with cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1996;111:45–54.PubMedCrossRefGoogle Scholar
Ascione R, Lloyd CT, Underwood MJ, et al. Inflammatory response after coronary revascularization with or without cardiopulmonary bypass. Ann Thorac Surg. 2000;69:1198–204.PubMedCrossRefGoogle Scholar
Gu YJ, MAriani MA, van Oeveren W, et al. Reduction of the inflammatory response in patients undergoing minimally invasive coronary artery bypass grafting. Ann Thorac Surg. 1998;65:420–4.PubMedCrossRefGoogle Scholar
Brasil LA, Gomes WJ, Salomao R, et al. Inflammatory response after myocardial revascularization with or without cardiopulmonary bypass. Ann Thorac Surg. 1998;66:56–9.PubMedCrossRefGoogle Scholar